1. Home
  2. OXSQ vs IPHA Comparison

OXSQ vs IPHA Comparison

Compare OXSQ & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oxford Square Capital Corp.

OXSQ

Oxford Square Capital Corp.

HOLD

Current Price

$1.90

Market Cap

151.9M

Sector

Finance

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.36

Market Cap

141.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OXSQ
IPHA
Founded
2003
1999
Country
United States
France
Employees
N/A
163
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.9M
141.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OXSQ
IPHA
Price
$1.90
$1.36
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
1.1M
23.6K
Earning Date
04-29-2026
03-26-2026
Dividend Yield
22.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.61
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.56
$1.18
52 Week High
$2.59
$2.63

Technical Indicators

Market Signals
Indicator
OXSQ
IPHA
Relative Strength Index (RSI) 62.02 46.46
Support Level $1.67 $1.18
Resistance Level $1.95 $1.80
Average True Range (ATR) 0.04 0.08
MACD 0.00 -0.00
Stochastic Oscillator 66.73 23.26

Price Performance

Historical Comparison
OXSQ
IPHA

About OXSQ Oxford Square Capital Corp.

Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: